Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Weizmann Institute of Science
Headquarters: Rehovot, Israel
Website: http://www.weizmann.ac.il
Year Founded: 1934
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 7, 2024
Discovery & Translation
Science Spotlight: Multi-epitope antivirals, metastatic transition, and more
BioCentury’s roundup of translational innovations also includes a study from Amgen and a newco spotlight
BioCentury | Sep 30, 2024
Discovery & Translation
If industry shifts toward unbiased discovery, can academia align?
The growing power of tools for holistically studying human biology should free researchers from narrow searches in discovery
BioCentury | Sep 27, 2024
Discovery & Translation
Three tensions in early-stage translation: BioCentury Grand Rounds
Across disciplines, researchers are navigating trade-offs in advancing translation that boil down to scope versus focus
BioCentury | Jan 27, 2024
Discovery & Translation
Genentech’s i-shaped Abs; a bispecific dendritic-T cell engager and more
BioCentury’s roundup of translational innovations
BioCentury | Oct 1, 2022
Discovery & Translation
An anti-IgE protein-bacteria combo for food allergy; predicting COVID mutants, Lasker winners and more
BioCentury’s roundup of translational news
BioCentury | Sep 10, 2022
Discovery & Translation
A suite of liquid biopsy approaches for cancer detection and more
BioCentury’s roundup of translational news
BioCentury | Jul 30, 2022
Data Byte
Assessing an expanse of ALS targets
Restoring neurotransmission may be the key to slowing fatal disease
BioCentury | Jan 26, 2022
Deals
Jan. 25 Quick Takes: Casdin Capital, GV lead $140M series B for Leyden
Plus Twist-Artisan, Monte Rosa-Weizmann, SeqOne, Mammoth and more
BioCentury | Sep 18, 2021
Product Development
Booster meeting outcome: FDA, manufacturers no longer aligned on COVID
Advisory committee meeting marked muddled messages from FDA, lack of coordination with Pfizer
BioCentury | Sep 16, 2021
Regulation
COVID vaccine booster decision hinges on sense of urgency
FDA advisory committee will assess data on booster efficacy, risks of acting or waiting
Items per page:
1 - 10 of 158